Takeda Bigs Up Entyvio As Pillar Of GI Plans
This article was originally published in PharmAsia News
Executive Summary
Amid generic challenges to some of its older mainstay products in the field, Takeda is aiming to convince investors that its commitment to, and prospects in, the gastrointestinal (GI) space remain solid.